The field of immunometabolism is a rapidly emerging and exciting area of investigation into the role of intracellular metabolic pathways in immune cells.
Changes to these pathways are pivotal in the development of severe diseases, including cancer and autoimmune conditions.
Immunometabolic therapies offer complementary and highly differentiated approaches to treating disease by correcting immune cell function and/or inhibiting tumour cell growth.
Sitryx is building a broad and differentiated pipeline by identifying novel targeted approaches based on how changes in metabolism modulate immune cell function.
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. Sitryx's proprietary science is led by a highly experienced management team.
Sitryx was co-founded in 2018 by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.
Seed funding was received from SV Health Investors and the Company raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. In 2020 Sitryx formed an exclusive global licensing and research collaboration with Eli Lilly and Company. Lilly also became an investor in the company. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.